Chrysanthi Sardeli,Paul Zarogoulidis,Christoforos Kosmidis et al.
Chrysanthi Sardeli et al.
Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled ad...
Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? [0.03%]
非小细胞肺癌免疫检查点抑制剂再挑战：不同的情况是否需要不同的解决方案？
Giulio Metro,Diego Signorelli
Giulio Metro
Identifying successful biomarkers for patients with non-small-cell lung cancer [0.03%]
非小细胞肺癌患者的成功生物标志物鉴定
Alex Friedlaender,Joshua Bauml,Giuseppe Luigi Banna et al.
Alex Friedlaender et al.
Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods [0.03%]
非小细胞肺癌的活检与复检：现有及未来的方法学研究
Paul Zarogoulidis,Christoforos Kosmidis,Varvara Fyntanidou et al.
Paul Zarogoulidis et al.
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study [0.03%]
阿法替尼治疗表皮生长因子受体常见突变的晚期非小细胞肺癌患者：一项四期临床研究
Sumitra Thongprasert,Sarayut L Geater,Dana Clement et al.
Sumitra Thongprasert et al.
Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. ...
Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid [0.03%]
立体定向体部放射治疗与分段放射治疗治疗支气管肺类癌的早期阶段的效果比较
Rodney E Wegner,Stephen Abel,Zachary D Horne et al.
Rodney E Wegner et al.
Aim: To compare trends and outcomes in early stage bronchopulmonary carcinoid (BPC) tumors treated nonoperatively with conventionally fractionated radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT). ...
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors [0.03%]
二甲双胍与免疫检查点抑制剂联合治疗非小细胞肺癌患者的临床疗效分析
Muhammad Z Afzal,Konstantin Dragnev,Tayyaba Sarwar et al.
Muhammad Z Afzal et al.
Aim: To study the clinical benefits of concurrent metformin and immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer patients. Materials & me...
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report [0.03%]
一例派姆单抗致肌炎的病例报告
Jonas Claus,Annelies Van Den Bergh,Sanne Verbeek et al.
Jonas Claus et al.
A 57-year-old man presented with swelling and pain in the lower limbs, inability to walk and increasing dyspnea for 2 days. Because of refractory stage IV non-small-cell lung cancer, pembrolizumab was started 21 days before presentation. Si...
Case Reports
Lung cancer management. 2019 May 8;8(2):LMT10. DOI:10.2217/lmt-2018-0017 2019
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer [0.03%]
免疫检查点抑制剂治疗后的挽救化疗疗效及安全性分析（肺癌）
Mari Tone,Takehiro Izumo,Nobuyasu Awano et al.
Mari Tone et al.
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. ...
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity? [0.03%]
RB1野生型小细胞肺癌和大细胞神经内分泌癌具有同一性的两种表现吗？
Dmitriy Sonkin,Anish Thomas,Beverly A Teicher
Dmitriy Sonkin
Until recently, small cell lung cancer (SCLC) was described as SCLC and SCLC variant, based upon cellular morphology and loss of neuroendocrine markers in the SCLC variant. However, based on recent research advances, driven in part by the i...